<DOC>
	<DOC>NCT00944918</DOC>
	<brief_summary>A partially-blind, randomised, multicentre phase III trial of Faslodex plus concomitant Arimidex versus Faslodex plus Arimidex-Placebo versus exemestane in postmenopausal locally advanced / metastatic breast cancer patients who have progressed on NSAIs. Randomisation to Faslodex ± Arimidex / Arimidex-Placebo or exemestane will be open (1:1:1). For Faslodex treated patients the randomisation to Arimidex or Arimidex-Placebo will be double-blind.</brief_summary>
	<brief_title>Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the breast. Metastatic disease must be measurable or evaluable Relapsed or progressed during prior treatment with singleagent NSAI, meeting either of the following criteria: NSAI given as adjuvant therapy that lasted ≥ 12 months OR Achieved an objective CR, PR, or SD that that lasted ≥ 6 months after prior 1stline Female postmenopausal patients Hormone receptor status1. ER ve and PgR NK2. ERve and PgR ve3. ER NK Prescribed Tamoxifen for metastatic disease Rapidly progressive visceral disease Patients with malignancies within the last 5 years.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>